RxDoctor Payments Data

Gregory Mayberry, MD

Family Medicine · Birmingham, ALNPI 1215285754

Payments from drug & device makers

$11,316in general payments, 2019–2025

Across 659 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$818
  • Johnson & Johnson$699
  • Amgen$667
  • Amarin Pharma, Inc.$523
  • plus $6K from 49 others

What the payments were for

  • Speaking & faculty fees$140%
  • Food & beverage$11,301100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,316 in reported general payments places this provider in the 90th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$36,003
Medicare patients
115
Services billed
445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide83$107,329
EliquisApixaban109$65,277
RybelsusSemaglutide29$50,209
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$29,144
JardianceEmpagliflozin28$23,751
MyrbetriqMirabegron25$19,532
LinzessLinaclotide19$18,355
XareltoRivaroxaban20$17,307
MounjaroTirzepatide17$15,481
JanuviaSitagliptin Phosphate37$11,105
JanumetSitagliptin Phos/Metformin Hcl11$10,975
TrulicityDulaglutide12$10,031
Atorvastatin Calcium524$6,825
Levothyroxine Sodium433$4,171
Losartan Potassium275$3,315

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,153$157,538112 claims
PfizerEliquis$434$65,277109 claims
GSKTrelegy Ellipta$221$29,14446 claims
Lilly USA, LLCMounjaro, Trulicity$818$25,51229 claims
Boehringer IngelheimJardiance$210$23,75128 claims
MerckJanuvia, Janumet$85$22,08148 claims
Astellas Pharma US IncMyrbetriq$18$19,53225 claims
AbbVieLinzess$1,897$18,35519 claims
Johnson & JohnsonXarelto$699$17,30720 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$36$4,171433 claims
Almatica Pharma LLCSertraline Hcl$177$73679 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →